# US 2025/0152601 A1 · Compositions and Methods for the Treatment of Sexual Dysfunctions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152601 A1
- Document ID: US20250152601A1
- Status: Published application
- Kind: A1
- Application number: 18/839,364
- Filed: 2023-01-23
- Published: 2025-05-15
- Earliest claimed: 2022-02-23
- Assignees: The Jonathan Hurt Living Trust
- Applicants: The Jonathan Hurt Living Trust
- Inventors: Jonathan Dale Hurt
- Web page: https://patentgrep.com/patent/US20250152601A1

## CPC

- A61K 31/185: Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids (hydroxamic acids A61K31/16; peroxy acids A61K31/327)
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/195: having an amino group
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 36/258: Panax (ginseng)
- A61K 36/324: Boswellia, e.g. frankincense
- A61K 36/53: Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K 36/67: Piperaceae (Pepper family), e.g. Jamaican pepper or kava
- A61K 36/81: Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K 36/84: Valerianaceae (Valerian family), e.g. valerian
- A61K 36/88: Liliopsida (monocotyledons)
- A61K 36/898: Orchidaceae (Orchid family)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/10: for impotence
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are compositions and methods for treating sexual dysfunctions including a reduction and/or an absence of tactile sexual function in the genitals, genital numbness, delayed ejaculation and/or failure to ejaculate, premature ejaculation, anorgasmia, decreased libido, erectile dysfunction, sexual anhedonia, post-selective serotonin reuptake inhibitor sexual dysfunction, or a combination thereof.

## Claims

### Claim at position 1

1-137. (canceled)

### Claim 138

A composition for treating a reduced amount of tactile sexual function, comprising:
at least one positive GABAergic treatment substance, wherein the at least one positive GABAergic treatment substance increases the amount of a GABAA receptor agonist after the person ingests the at least one positive GABAergic treatment substance; and
at least one negative glutamatergic treatment substance, at least another positive GABAergic treatment substance, or a combination thereof;
wherein the at least one positive GABAergic treatment substance comprises at least one precursor of GABA, at least one GABA prodrug, at least one GABAA receptor agonist, or a combination thereof;
wherein the at least one negative glutamatergic treatment substance promotes the activation of the mGlu2 receptor, the mGlu3 receptor, or a combination thereof; and wherein the at least another positive GABAergic treatment substance activates a TRPV1-Receptor and activates a KCC2 transporter;
wherein the at least one positive GABAergic treatment substance and the at least one negative glutamatergic treatment substance, at least another positive GABAergic treatment substance, or a combination thereof, are in an effective amount to achieve pleasurable tactile sexual function just before the beginning of orgasm, just after the beginning of orgasm, or both, in a person.

### Claim 139 (depends on 138)

The composition of claim 138, further excluding:
at least one negative GABAergic treatment substance, a positive glutamatergic treatment substance, or a combination thereof;
wherein the negative GABAergic treatment substance comprises a carbonic anhydrase inhibitor;
wherein the positive glutamatergic treatment substance activates at least one NMDA receptor, decreases KCC2 activity, or a combination thereof; and
wherein the at least one negative GABAergic treatment substance, the positive glutamatergic treatment substance, or the combination thereof is in an effective amount to reduce tactile sexual function, increase the time to ejaculation, or both.

### Claim 140 (depends on 139)

The composition of claim 139, wherein:
the carbonic anhydrase inhibitor comprises apigenin, hesperidin, luteolin, mangosteen, spermidine, or a combination thereof; and
the positive glutamatergic treatment substance that activates at least one NMDA receptor, decreases KCC2 activity, or a combination thereof comprises NMDA.

### Claim 141 (depends on 138)

The composition of claim 138, wherein:
the at least one precursor of GABA comprises at least one branched chain amino acid;
the at least one branched chain amino acid is selected from leucine, isoleucine, valine, or a combination thereof;
the at least one GABA prodrug comprises nicotinoyl-GABA;
the at least one GABAA receptor agonist comprises homotaurine;
the at least one negative glutamatergic treatment substance comprises at least one positive cysteineic treatment substance, noopept, or a combination thereof;
the at least one positive cysteineic treatment substance comprises N-acetyl-cysteine, cysteine, cystine; or a combination thereof; and
the at least one treatment substance that activates a TRPV1-receptor and activates a KCC2 transporter comprises piperine, vanillin, or a combination thereof.

### Claim 142 (depends on 141)

The composition of claim 141; wherein:
the leucine is about 10.1 mg per kilogram body weight to about 116.1 mg per kilogram body weight;
the isoleucine is about 10.1 mg per kilogram body weight to about 48.4 mg per kilogram body weight;
the valine is about 10.1 mg per kilogram body weight to about 116.1 mg per kilogram body weight;
a combination thereof of leucine, isoleucine, and valine is about 60.7 mg per kilogram body weight to about 99.2 mg per kilogram body weight;
the nicotinoyl-GABA is about 1.5 mg per kilogram body weight to about 8.1 mg per kilogram body weight;
the homotaurine is about 0.7 mg per kilogram body weight to about 3.2 mg per kilogram body weight;
the N-acetyl-cysteine is about 3.7 mg per kilogram body weight to about 32.3 mg per kilogram body weight;
the cysteine, cystine, or both is about 7.4 mg per kilogram body weight to about 8.1 mg per kilogram body weight;
the noopept is about 0.4 mg per kilogram body weight to about 1.5 mg per kilogram body weight; and
the piperine is about 0.22 mg per kilogram body weight to about 0.24 mg per kilogram body weight.

### Claim 143 (depends on 141)

The composition of claim 141, wherein the at least one branched chain amino acid consists essentially of valine.

### Claim 144 (depends on 138)

The composition of claim 138, further comprising another at least one positive GABAergic treatment substance that:
increases the amount of a GABA receptor positive allosteric modulator;
increases the amount of a GABA receptor positive allosteric modulator and is a negative glutamatergic treatment substance;
inhibits a GABA transaminase, activates a glutamic acid decarboxylase;
inhibits a GAT transporter;
increases the amount of a GABA receptor agonist;
promotes a KCC2 transporter gene expression; or
a combination thereof.

### Claim 145 (depends on 144)

The composition of claim 144, wherein the another at least one positive GABAergic treatment substance that:
increases the amount of a GABA receptor positive allosteric modulator comprises a Boswellia serrata preparation, a Crocus sativus preparation, a Piper methysticum preparation, theanine, a baicalin preparation, or a combination thereof;
increases the amount of a GABA receptor positive allosteric modulator and is a negative glutamatergic treatment substance comprises magnesium threonate;
inhibits GABA transaminase comprises a Melissa officinalis preparation;
activates glutamic acid decarboxylase comprises a Valeriana officinalis preparation;
inhibits a GAT transporter comprises taurine;
increases the amount of a GABA receptor agonist comprises GABA, a Withania somnifera preparation, or a combination thereof; and
promotes a KCC2 transporter gene expression comprises trans-resveratrol.

### Claim 146 (depends on 145)

The composition of claim 145, wherein:
the Boswellia serrata preparation is about 3.7 mg per kilogram body weight to about 4.0 mg per kilogram body weight;
the Crocus sativus preparation is about 2.6 mg per kilogram body weight to about 2.9 mg per kilogram body weight;
the Piper methysticum preparation is about 4.3 mg per kilogram body weight to about 20.6 mg per kilogram body weight;
the theanine is about 5.9 mg per kilogram body weight to about 9.7 mg per kilogram body weight;
the baicalin preparation is about 4.0 mg per kilogram body weight to about 13.1 mg per kilogram body weight;
the magnesium threonate is about 9.8 mg per kilogram body weight to about 84.0 mg per kilogram body weight;
the Melissa officinalis preparation is about 16.5 mg per kilogram body weight to about 29.0 mg per kilogram body weight;
the Valeriana officinalis preparation is about 14.7 mg per kilogram body weight to about 35.5 mg per kilogram body weight;
the taurine is about 14.7 mg per kilogram body weight to about 16.1 mg per kilogram body weight;
the GABA is about 22.1 mg per kilogram body weight to about 24.2 mg per kilogram body weight;
the Withania somnifera preparation is about 4.4 mg per kilogram body weight to about 4.8 mg per kilogram body weight; and
the trans-resveratrol is about 7.4 mg per kilogram body weight to about 8.1 mg per kilogram body weight.

### Claim 147 (depends on 138)

The composition of claim 138, further comprising at least one positive cholinergic treatment substance.

### Claim 148 (depends on 147)

The composition of claim 147, wherein the at least one at least one positive cholinergic treatment substance comprises:
at least one acetylcholinesterase inhibitor;
at least one acetylcholine precursor; or
a combination thereof.

### Claim 149 (depends on 148)

The composition of claim 148, wherein:
the at least one acetylcholinesterase inhibitor comprises a Panax genus preparation;
huperzine A, galantamine HBr, or a combination thereof; and
the at least one acetylcholine precursor comprises alpha-glycerophosphocholine, centrophenoxine, or a combination thereof.

### Claim 150 (depends on 149)

The composition of claim 149, wherein:
the Panax genus preparation is about 8.8 mg per kilogram body weight to about 9.7 mg per kilogram body weight;
the huperzine A is about 0.00074 mg per kilogram body weight to about 0.00161 mg per kilogram body weight;
the galantamine HBr is about 0.59 mg per kilogram body weight to about 0.194 mg per kilogram body weight;
the alpha glycerophosphocholine is about 4.4 mg per kilogram body weight to about 4.8 mg per kilogram body weight; and
the centrophenoxine is about 7.4 mg per kilogram body weight to about 8.1 mg per kilogram body weight.

### Claim 151 (depends on 149)

The composition of claim 149, wherein the at least one acetylcholinesterase inhibitor consists essentially of galantamine HBr.

### Claim 152 (depends on 138)

The composition of claim 138, further comprising:
at least one positive cannabinoidergic treatment substance;
at least one positive nitroergic treatment substance;
at least negative adenosinergic treatment substance;
at least one positive glycinergic treatment substance; or
a combination thereof.

### Claim 153 (depends on 152)

The composition of claim 152, wherein
the at least one positive cannabinoidergic treatment substance comprises a Syzygium aromaticum preparation, calcium pyruvate, oleamide, or a combination thereof;
the at least one positive nitroergic treatment substance comprises norvaline, icariin, or a combination thereof;
the at least one negative adenosinergic treatment substance comprises theobromine, caffeine, or a combination thereof; and
the at least one positive glycinergic treatment substance comprises glycine, pramiracetam, or a combination thereof.

### Claim 154 (depends on 153)

The composition of claim 153, wherein:
the Syzygium aromaticum preparation is about 4.4 mg per kilogram body weight to about 4.8 mg per kilogram body weight;
the calcium pyruvate is about 13.2 mg per kilogram body weight to about 29.0 mg per kilogram body weight;
the oleamide is about 0.7 mg per kilogram body weight to about 3.2 mg per kilogram body weight;
the norvaline is about 3.9 mg per kilogram body weight to about 35.0 mg per kilogram body weight;
the icariin is about 0.88 mg per kilogram body weight to about 0.97 mg per kilogram body weight;
the theobromine is about 17.6 mg per kilogram body weight to about 19.4 mg per kilogram body weight;
the caffeine is about 1.5 mg per kilogram body weight to about 3.2 mg per kilogram body weight;
the glycine is about 14.7 mg per kilogram body weight to about 64.5 mg per kilogram body weight; and
the pramiracetam is about 3.7 mg per kilogram body weight to about 10.1 mg per kilogram body weight.

### Claim 155 (depends on 138)

A method for treating a reduced amount of tactile sexual function, comprising:
ingesting a first composition in accordance with claim 138, and wherein tactile sexual stimulation occurs between about 5 minutes to about 120 minutes after ingesting the first composition.

### Claim 156 (depends on 138, 155)

The method of claim 155, further comprising:
ingesting at least another composition in accordance with claim 138 within 5 to 60 minutes of ingesting said first composition, and wherein tactile sexual stimulation occurs between about 5 minutes to about 120 minutes after ingesting said at least another composition.

### Claim 157 (depends on 138)

A kit for treating a reduced amount of tactile sexual function and protecting a person from transmission of a sexually transmitted disease, an undesired pregnancy during sexual intercourse, or both, comprising:
at least one composition in accordance with claim 138; and
at least one condom, a wearable ring on a penis that comprises a vibrating devise, or a combination thereof.
